摘要
目的评价喹诺酮类药物治疗妇科急性盆腔炎的疗效和安全性。方法将173例带有13种157株致病菌的急性盆腔炎患者随机分为两组,治疗组(123例)中用莫西沙星治疗40例,加替沙星治疗41例,左氧氟沙星治疗42例,均采取高剂量序贯疗法,对照组(50例)用氧氟沙星治疗,两组疗程均为7～14d。结果治疗组与对照组临床有效率分别为98.4%(121/123)和88.0%(44/50),致病菌清除率分别为93.86%(107/114)和83.72%(36/43),平均疗程分别为(6.06±1.22)d和(8.33±1.66)d,两组比较,P均<0.05。莫西沙星和加替沙星抗菌谱几乎能覆盖盆腔炎的13种致病菌,左氧氟沙星对军团菌、衣原体、支原体作用稍差,高剂量序贯疗法短期足量用药亦能有效治疗妇科急性盆腔炎。治疗过程中未出现严重不良反应。结论莫西沙星、加替沙星、左氧氟沙星治疗妇科急性盆腔炎安全、有效。
Objective To evaluate the efficacy and safety of fluoroquinolones in the treatment of women＇s acute pelvic inflammatory disease （APID）. Methods All 173 cases of APID with 13 bacterial flora in 157 pathogenes were randomly assigned to the treatment group （123 cases） and the control group （50 cases）. There were 40 cases with moxifloxacin, 41 cases with gatifloxacin and 42 cases with levofloxacin in the treatment group. The large dose-sequential therapy were done. In the control group 50 cases were treated with ofloxacin. The treatment courses were all 7- 14 d. The clinical observation and comparative researth were done. Results The clinical effective rates in the treatment and control groups were 98.37% （121/123） and 88.00% （44/50） respectively, the bacterial clearance rates were 93.86% （107/114） and 83.72% （36/43） respectively. The treatment courses were （6.06 ± 1.22）d and （8.33 ± 1.66）d, respectively, P 〈 0. 05. No severe adverse reaction occurred in three treatment groups. Conclusion Moxifloxacin, gatifloxacin and levofloxaein is very effective and safe for the treatment of APID.
出处
《中国药业》
CAS
2007年第11期47-48,共2页
China Pharmaceuticals
关键词
莫西沙星
加替沙星
左氧氟沙星
高剂量序贯疗法
急性盆腔炎
moxifloxacin
gatifloxacin
levofloxacin
large dose - sequential therapy
acute pelvic inflammatory disease
